← Back to Search

NeuroCOVID Group for Memory Loss

N/A
Recruiting
Led By Judith M Ford, PhD
Research Sponsored by San Francisco Veterans Affairs Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

Study Summary

The novel coronavirus SARS-CoV-2 infection, COVID, continues to rage throughout the world with 115,000,000 confirmed cases and over 2,500,000 deaths (as of Mar 3, 2021). This translates to millions of people surviving COVID19 infection. While the lungs are ground zero, COVID tears through organ systems from brain to blood vessels. We are now beginning to see people recover but complain of ongoing problems, including lingering cognitive problems, depression, and anxiety. We have brought together 2 laboratories with complementary techniques including psychological testing and neuroimaging methods togethers with markers in the blood that may signal damage in the brain. A close look at these problems is timely and imperative if we are to understand the pathophysiology of 'COVID brain' and prepare for downstream problems.

Eligible Conditions
  • COVID Syndrome
  • Memory Loss
  • Attention Deficit Disorder
  • Coronavirus Pandemic
  • Brain Fog
  • COVID-19
  • Coronavirus
  • Fatigue

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change of Neuropsychological Test Performance
Number of Participants with Blood Biomarkers
Number of Participants with EEG Latency & Amplitude
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: NeuroCOVID GroupExperimental Treatment1 Intervention
Individuals (ages 18-70 years) who endorse a reported change in concentration, memory, feelings anxiety or depression since initial COVID infection.
Group II: COVID Control GroupExperimental Treatment1 Intervention
Individuals (ages 18-70 years) who do not feel any different since recovering from initial COVID infection.

Find a Location

Who is running the clinical trial?

San Francisco Veterans Affairs Medical CenterLead Sponsor
48 Previous Clinical Trials
210,613 Total Patients Enrolled
Judith M Ford, PhDPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~44 spots leftby Jun 2025